A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2004
12/29/2004	WO2004066951A3 Quinoline derivatives as nk-2 and nk-3 receptor antagonists
12/29/2004	WO2004064743A3 Modified retinoid compounds and their uses
12/29/2004	WO2004064733A3 The use of c-raf inhibitors for the treatment of neurodegenerative diseases
12/29/2004	WO2004064727A3 Method of cancer treatment using hdac inhibitors
12/29/2004	WO2004058329A3 Ester combination local anesthetic
12/29/2004	WO2004050062A3 Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
12/29/2004	WO2004048419A9 Method of classifying, purifying and using fenugreek seeds
12/29/2004	WO2004046068A3 Non-steroidal farnesoid x receptor modulators and methods for the use thereof
12/29/2004	WO2004043433A3 Pharmaceutical antiviral compositions
12/29/2004	WO2004026232A3 Vaginal health products
12/29/2004	WO2004014307A3 Gal3 antagonists for the treatment of neuropathic pain
12/29/2004	WO2004009091A8 Purine derivatives as liver x receptor agonists
12/29/2004	WO2004004684A8 Controlled-release pharmaceutical formulations
12/29/2004	WO2004002940A8 Inhibitors of hcv ns5b polymerase
12/29/2004	WO2003103671A8 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
12/29/2004	WO2003102097A8 The hydrochloride of (s)-(+)-3-[1-[2-(1-acetyl-2,3-dihydro-1h-indol-3-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-6-chloro-1h-indole
12/29/2004	WO2003063882A8 Cycloglycans suitable to inhibit mammalian infection
12/29/2004	WO2003045392A8 Use of n-(indolcarbonyl-)piperazine derivatives
12/29/2004	WO2003035790A9 Improved method for generating an aerosol
12/29/2004	WO2003015797A8 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
12/29/2004	WO2002089747A3 Compositions and methods for the therapy and diagnosis of prostate cancer
12/29/2004	WO2002043648A3 Compounds active at the glucocorticoid receptor ii
12/29/2004	EP1491628A1 Novel galactose transferases, peptides thereof and nucleic acid encoding the same
12/29/2004	EP1491551A1 Estrone derivative and process for producing the same
12/29/2004	EP1491544A1 Benzo[a]pyrano[3,2-h]acridin-7-one derivatives, processes for their preparation and pharmaceutical compositions thereof
12/29/2004	EP1491543A1 Intermediate compounds
12/29/2004	EP1491542A2 Intermediate compounds
12/29/2004	EP1491541A1 Pyridazinone aldose reductase inhibitors
12/29/2004	EP1491540A1 Pyridazinone aldose reductase inhibitors
12/29/2004	EP1491538A1 Anti-mitotic agents which inhibit tubulin polymerization
12/29/2004	EP1491537A1 Hydroxymorpholinone derivative and medicinal use thereof
12/29/2004	EP1491534A1 Novel hairpin polyamide
12/29/2004	EP1491533A2 Quinoline-and naphthalenecarboxamides, pharmaceutical compositions thereof and their use as calpain inhibitors
12/29/2004	EP1491532A1 Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetyloholine receptors
12/29/2004	EP1491531A1 (1-indanone)-(1,2,3,6-tetrahydropyridine) derivative
12/29/2004	EP1491524A2 Selective androgen receptor modulators and methods of use thereof
12/29/2004	EP1491217A1 Stabilization of polynucleotide complexes
12/29/2004	EP1491212A1 Remedy for sleep disturbance
12/29/2004	EP1491211A1 Remedy for glioblastoma
12/29/2004	EP1491206A1 Induction method for cell differentiation
12/29/2004	EP1491201A1 Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides
12/29/2004	EP1491200A1 Use of pyridoxal phosphate derivatives for the treatment of diabetes and related complications
12/29/2004	EP1491199A1 Pharmaceutical compositions of alendronate sodium trihydrate and process for the preparation thereof
12/29/2004	EP1491198A1 use of vitamin d derivatives to enhance efficacy of cytotoxic agents
12/29/2004	EP1491197A1 Pharmaceutical composition comprising voacamine for the stimulation and modulation of the human immunologic system
12/29/2004	EP1491196A2 Method for treatment of CNS-involved lysosomal storage diseases
12/29/2004	EP1491195A1 Pharmaceutical formulations comprising amoxicillin and clavulanate
12/29/2004	EP1491194A1 Vdac regulator
12/29/2004	EP1491193A1 Therapeutic combinations comprising amlodipine and atorvastatin
12/29/2004	EP1491192A1 Biological activity-promoting compositions containing soybean germ-origin isoflavone aglycon
12/29/2004	EP1491191A1 Extracts from Lychee (Litchi sinensis) containing oligomeric proanthocyanidines
12/29/2004	EP1491189A1 Diclofenac sodium oral pharmaceutical
12/29/2004	EP1491188A1 Topical use of valproic acid for the prevention or treatment of skin disorders
12/29/2004	EP1491187A1 Preventive or therapeutic agent for kidney disease
12/29/2004	EP1491183A2 Use of a plant extract of the Rosaceae family
12/29/2004	EP1490696A2 Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs)
12/29/2004	EP1490690A2 Novel compositions and methods in cancer associated with altered expression of mcm3ap
12/29/2004	EP1490686A2 Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
12/29/2004	EP1490519A2 Life sciences business systems and methods
12/29/2004	EP1490502A2 Screening method for predicting susceptibility to breast cancer
12/29/2004	EP1490500A1 Novel compositions and methods in cancer associated with altered expression of tbx21
12/29/2004	EP1490490A2 Antisense iap nucleobase oligomers and uses thereof
12/29/2004	EP1490393A1 11beta-substituted 19-nor-17alpha-pregna-1,3,5(10)-trien-17beta-ols with a 21,16alpha-lactone ring
12/29/2004	EP1490392A1 Steroidal quinols as prodrugs of antioxidants
12/29/2004	EP1490391A1 19-nor-17alpha-pregna-1,3,5(10)-trien-17beta-ols with a 21,16alpha-lactone ring substituted with a long chain at the 11beta position
12/29/2004	EP1490388A1 Novel compositions and methods in cancer associated with altered expression of kcnj9
12/29/2004	EP1490387A2 A human ribonucleotide reductase m2 subunit
12/29/2004	EP1490386A2 Novel polypeptides and nucleic acids encoding the same
12/29/2004	EP1490382A1 Process of preparing azithromycin and crystalline 9-deoxo-9a-aza-9a-homoerythromycin a hydrate used therein
12/29/2004	EP1490374A2 Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
12/29/2004	EP1490373A1 Inhibitors of nucleoside phosphorylases and nucleosidases
12/29/2004	EP1490371A1 Thiopene-based tricyclic compounds and pharmaceutical compositions comprising same
12/29/2004	EP1490367A1 Imidazopyridine derivatives as kinase inhibitors
12/29/2004	EP1490366A1 Novel alkoxypyridine-derivatives
12/29/2004	EP1490365A1 Azaindoles as inhibitors of c-jun n-terminal kinases
12/29/2004	EP1490364A1 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
12/29/2004	EP1490363A1 Methods of preparation of the 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone
12/29/2004	EP1490361A1 Polycyclic compounds as potent alpha2-adrenoceptor antagonists
12/29/2004	EP1490360A1 Thiazolidinedione derivatives and pharmaceutical composition comprising the same
12/29/2004	EP1490358A1 6-(4-substituted-anilino)pyrimidine derivatives, method for the preparation thereof and antiviral pharmaceutical composition comprising the same
12/29/2004	EP1490357A1 Stable hydrate of a muscarinic receptor antagonist
12/29/2004	EP1490356A1 (3z)-3-(3-hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
12/29/2004	EP1490355A1 Indolylmaleimide derivatives
12/29/2004	EP1490354A1 4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity
12/29/2004	EP1490352A1 Synthesis of piperidine and piperazine compounds as ccr5 antagonists
12/29/2004	EP1490350A1 Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase
12/29/2004	EP1490349A1 Therapeutic ion channel blocking agents and methods of use thereof
12/29/2004	EP1490344A2 Anxiolytic agents with reduced sedative and ataxic effects
12/29/2004	EP1490343A1 New aryl imidazoles and related compounds as c5a receptor modulators
12/29/2004	EP1490341A1 Novel adamantane derivatives
12/29/2004	EP1490340A1 Heteroaromatic urea derivatives as vr-1 receptor modulators for treating pain
12/29/2004	EP1490339A1 Novel chalcone derivatives and uses thereof
12/29/2004	EP1490338A1 Use of an alfa2-adrenoreceptor antagonist for cns-related diseases
12/29/2004	EP1490336A1 Piperidine or 8-aza-bicyclo(3.2.1)oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5)
12/29/2004	EP1490335A2 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
12/29/2004	EP1490334A1 Phthalimido derivatives as inhibitors of monoamine oxidase b
12/29/2004	EP1490328A1 Compositions and methods for inhibition of phospholipase a2 mediated inflammation
12/29/2004	EP1490324A2 Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors
12/29/2004	EP1490317A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
12/29/2004	EP1490120A1 Embolization

1 ... 4841 4842 4843 4844 4845 4846 4847 4848 4849 4850 4851 4852 4853 4854 4855 4856 4857 4858 4859 4860 4861 ... 7860